dose group
Subjects received one dose of 5E10 vp Ad5‐nCoV at 18–60 years old
Experimental: middle‐dose group
Subjects received one dose of 1E11 vp Ad5‐nCoV at 18–60 years old
Experimental: high‐dose group subjects received one dose of 1.5E11vp Ad5‐nCoV at 18–60 years old  I  Primary (0–7 days postvaccination):
Safety indexes of adverse reactions
Secondary (0–28 days postvaccination, within 6 mouths postvaccination):
Safety indexes of adverse events, Safety indexes of SAE, Safety indexes of lab measures, Immunogencity indexes of GMT (ELISA), Immunogencity indexes of GMT (pseudoviral neutralization test method) (Day 14, 28, Month 6 postvaccination),